Mesirow Financial Investment Management Inc. Has $48.92 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Posted by George Bondi on May 14th, 2026

Mesirow Financial Investment Management Inc. lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 5.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 84,420 shares of the medical research company’s stock after selling 4,991 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.0% of Mesirow Financial Investment Management Inc.’s portfolio, making the stock its 22nd biggest position. Mesirow Financial Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $48,918,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. JPL Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $28,000. Beacon Financial Strategies CORP bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Olistico Wealth LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Cloud Capital Management LLC bought a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $31,000. Finally, KERR FINANCIAL PLANNING Corp bought a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $38,000. 89.23% of the stock is owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 2.8%

Shares of NYSE TMO opened at $446.50 on Thursday. The stock has a market capitalization of $165.93 billion, a PE ratio of 24.55, a P/E/G ratio of 2.03 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The business’s fifty day moving average price is $488.70 and its 200-day moving average price is $543.73. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were issued a $0.47 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend was Friday, March 13th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 10.34%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent analyst reports. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Citigroup upped their price objective on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Barclays reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Morgan Stanley reaffirmed an “overweight” rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Finally, Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $619.65.

Get Our Latest Stock Report on TMO

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.